|
| |
|
| |
|
| |
Welcome to PharmaShots Weekly
| | | Mar 16 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
| |
Lonza’s $3B Divestment Paves Way for Pure-Play CDMO Growth
|
|
| | Servier Secures Day One Biopharma in $2.5B Pediatric Oncology Play
|
|
| | Enodia Bolsters Targeted Protein Strategy with Kezar Sec61 Acquisition
|
|
| | Agilent Strengthens Pathology & IVD Portfolio with $950M Biocare Deal
|
|
|
|
|
| |
Stay Curious.
| | | Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
| |
|
| |
|
| |
Cover Story
|
| |
Immutep Phase III Shock: Immunotherapy trial halted, stock plunges 80%
|
| |
Biopharma Partnerships & Expansion
|
| |
| • | GSK & Alfasigma: $690M linerixibat deal for PBC itch
|
|
| • | George Medicines & Ahngook: Triple-combo hypertension pill in South Korea
|
|
| • | Curatis & Neupharma: $107M Japan licensing for brain edema therapy
|
|
| • | C2N & BeauBrain: Alzheimer’s blood test expansion in South Korea
|
|
| • | PRISM & Receptor.AI: AI-driven discovery of ‘undruggable’ targets
|
|
| |
Precision Therapy & Pipeline Moves
|
| |
| • | Enodia: Next-gen targeted protein modulation via Sec61
|
|
| • | Servier: Pediatric oncology pipeline boost
|
|
| • | Agilent: Diagnostics and pathology expansion
|
|
| • | Medtronic: $550M Scientia Vascular acquisition for stroke care
|
|
| |
Clinical Trial Updates
|
| |
| • | Multiple Myeloma (RRMM): BMS SUCCESSOR-2 Phase II/III topline results
|
|
| • | Atopic Dermatitis (AD): Pfizer tilrekimig Phase II results
|
|
| • | Psoriatic Arthritis (PsA): UCB Bimzelx outperforms Risankizumab
|
|
| • | Chronic Limb-Threatening Ischemia (CLTI): Aplagon HEALING Phase IIa trial
|
|
| • | Phenylketonuria (PKU): Otsuka repinatrabit OLE data
|
|
| • | Ornithine Transcarbamylase (OTC) Deficiency: Ultragenyx DTX301 Phase III
|
|
| • | Type 2 Diabetes (T2D): Insulet fully closed-loop system EVOLUTION 2C study
|
|
| |
Regulatory Pulse
|
| |
| • | FDA approvals, Priority Reviews, Fast-Track designations
|
|
| • | Key highlights: BMS, Incyte, AstraZeneca/Daiichi, J&J, LENZ, ARTHEx, GSK
|
|
| |
MedTech Pulse
|
| |
| • | Pulse Biosciences nPulse Vybrance System for thyroid nodules
|
|
| • | QIAGEN QIAstat-Dx GI Panels clearance
|
|
| • | Cairn Surgical BCL System FDA submission
|
|
| |
Genomics & Rare Disease Innovations
|
| |
| • | Natera Zenith Genomics: WGS + long-read platform for rare disease detection
|
|
| |
|
| |
|
| |
|
| |
Celebrating Innovation and Excellence Across the Global Pharma & Healthcare Industry
|
| |
We are thrilled to announce the PharmaShots Pharma Awards 2026, a premier virtual event dedicated to recognizing groundbreaking innovation, leadership, and excellence in the pharmaceutical and healthcare sectors worldwide.
|
| |
This prestigious initiative brings together industry leaders, innovators, and key decision-makers from around the globe, creating a unique platform to celebrate achievements and set new benchmarks for the industry.
|
| |
Why Partner with PharmaShots Pharma Awards?
|
| |
Our sponsorship opportunities allow partners to:
|
| |
| • | Showcase your brand in front of a highly engaged, global pharma audience.
|
|
| • | Position your organization as a leader in innovation and thought leadership.
|
|
| • | Gain exclusive networking access to decision-makers, innovators, and influencers shaping the future of healthcare.
|
|
| |
We are currently reaching out to potential sponsors to understand your engagement goals and preferred sponsorship avenues. Based on your input, our team will provide a customized sponsorship prospectus detailing benefits, opportunities, and recommended next steps.
|
| |
Date of Awards Announcement: May 1, 2026
|
| |
We invite organizations to join us in this landmark celebration. Your support will help us highlight excellence, inspire innovation, and strengthen connections across the global pharma ecosystem.
|
| |
Interested in exploring sponsorship opportunities?
Partner with us at the PharmaShots Pharma Awards, fill out your sponsorship form here
|
| |
|
| |
|
| |
Immutep’s Phase III Shock: Immunotherapy Hopes Crumble, Stock Sinks 80%
|
| |
|
| |
In a gut-punch to the biotech world, Immutep revealed the unexpected failure of its pivotal Phase III trial testing eftilagimod alfa (efti)—its promising LAG‑3 immunotherapy—in combination with Merck’s Keytruda for first-line advanced non-small cell lung cancer (NSCLC).
|
| |
The high-stakes trial, spanning 25+ countries and 756 patients, was meant to redefine first-line NSCLC care. But in a stunning twist, the independent data monitoring committee halted the study for futility, sending Immutep’s stock tumbling 80%, from $2.76 to $0.50 premarket—a shocking blow for investors and immunotherapy enthusiasts alike.
|
| |
Efti had captured attention after Phase IIb success in head and neck cancer, boasting a 35.5% objective response rate and 12.9% complete responses, creating high expectations for this lung cancer study. The collapse of these expectations has left the biotech community scrambling to reassess the promise of LAG‑3 targeted therapies.
|
| |
CEO Marc Voigt acknowledged the disappointment and surprise, emphasizing that Immutep remains committed to its pipeline and will dig deep into the data to chart the next steps. Analysts call the outcome “jaw-dropping”, a reminder that even therapies with prior strong signals can stumble at the final hurdle.
|
| |
This is more than a stock drop—it’s a wake-up call for immuno-oncology, spotlighting the thin line between breakthrough and setback. For Immutep, the road ahead will test strategy, resilience, and credibility in a high-risk, high-reward arena.
|
| |
|
| |
| | Big Deals, Bold Bets: Pharma Partnerships and Power Plays
|
|
|
|
|
| |
Lonza’s $3B Power Move: The Strategic Exit That Fuels Its CDMO Future
|
| |
|
| |
Lonza has agreed to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds for CHF 2.3B (~$3B). Lonza receives CHF 1.7B (~$2.2B) upfront, retains a 40% stake, and expects total undiscounted proceeds of at least CHF 3B (~$4B) via cash, stake sale, and exit rights. Funds will drive CDMO expansion, with CHF 500M returned to shareholders via buyback; deal closes H2 2026.
|
| |
Why It Matters
|
| |
| • | Deal Structure: Upfront cash + retained stake secures ~$4B total value, prioritizing CDMO growth.
|
|
| • | Capital Allocation: Bolsters high-growth contract development and manufacturing services.
|
|
| • | Transformation Milestone: Advances “One Lonza” strategy as pure-play CDMO leader post-prior divestments.
|
|
| |
Strategic Focus
|
| |
| • | Sharpened Portfolio: Exits non-core CHI to double down on biopharma CDMO.
|
|
| • | Shareholder Returns: CHF 500M buyback signals confidence in core business.
|
|
| • | Growth Acceleration: Frees capital for expansion in booming CDMO market.
|
|
| • | Regional Execution: Builds on Monteggio site sale and tech divestments.
|
|
| |
This positions Lonza as the undisputed CDMO powerhouse for biopharma's next wave.
|
| |
GSK Strikes $690M+ Linerixibat Deal with Alfasigma to Advance PBC Itch Treatment
|
| |
GSK has granted Alfasigma worldwide exclusive rights to late-stage linerixibat for cholestatic pruritus in primary biliary cholangitis (PBC). GSK gets $300M upfront, plus milestones including $100M on U.S. FDA approval (PDUFA March 24, 2026), $20M on EU/UK nods, up to $270M in sales milestones, and tiered double-digit royalties.
|
| |
Why It Matters
|
| |
| • | Deal Value: $300M upfront + $390M+ milestones/royalties total $690M+ potential.
|
|
| • | Clinical Strength: Phase III GLISTEN trial hit primary/secondary endpoints for rapid, sustained itch relief and sleep improvement.
|
|
| • | Regulatory Momentum: Under review in U.S., EU, UK, China (priority), Canada.
|
|
| |
Strategic Focus
|
| |
| • | Patient Impact: Targets debilitating PBC itch, a major unmet need.
|
|
| • | Alfasigma Expansion: Builds rare liver disease portfolio with global rights.
|
|
| • | GSK Streamline: Monetizes asset amid multi-region reviews.
|
|
| • | Market Potential: First targeted pruritus therapy if approved.
|
|
| |
This deal accelerates linerixibat toward transforming lives in PBC while boosting Alfasigma's liver disease leadership.
|
| |
George Medicines Expands Asia Strategy with Korea Deal for Triple-Combo Hypertension Pill
|
| |
|
| |
George Medicines has inked an exclusive licensing and supply deal with Ahngook Pharmaceutical for GMRx2 in South Korea. Ahngook handles regulatory approval and commercialization; George gets upfront fees, regulatory/commercial milestones, and stepped royalties.
|
| |
Why It Matters
|
| |
| • | Deal Structure: Upfront + milestones/royalties fuel George’s global push.
|
|
| • | Product Innovation: Single-pill GMRx2 combines Telmisartan, Amlodipine, Indapamide in 3 strengths for simplified hypertension control.
|
|
| • | Market Access: Targets Korea’s cardiovascular needs via Ahngook’s local expertise.
|
|
| |
Strategic Focus
|
| |
| • | Asia Expansion: Builds George’s footprint in high-growth hypertension markets.
|
|
| • | Patient Benefits: Enables early, sustained BP reduction with proven components.
|
|
| • | Partner Synergy: Strengthens Ahngook’s cardio portfolio.
|
|
| • | Global Scale: Advances fixed-dose combo toward broader adoption.
|
|
| |
This partnership accelerates GMRx2’s rollout, tackling hypertension’s global burden one market at a time.
|
| |
Curatis Unlocks $107M Japan Opportunity with Neupharma Deal for Brain Edema Therapy
|
| |
Curatis has signed an exclusive licensing and development deal with Neupharma for corticorelin (C-PTBE-01) in Japan to treat peritumoral brain edema in brain tumors. Neupharma funds pivotal PMDA trial and commercialization; Curatis gets upfront + up to CHF 83.5M (~$107M) milestones and 20% royalties.
|
| |
Why It Matters
|
| |
| • | Deal Value: Upfront + $107M milestones/20% royalties for Japan rights.
|
|
| • | Unmet Need: Targets tumor-related brain swelling, starting with kids/teens.
|
|
| • | Regulatory Path: PMDA meeting summer 2026; trial start 2027.
|
|
| |
Strategic Focus
|
| |
| • | Japan Acceleration: Neupharma drives local development/commercialization.
|
|
| • | Global Synergy: Aligns with U.S./EU Phase III prep for broader approval.
|
|
| • | Pediatric Priority: Addresses critical gap in brain tumor complications.
|
|
| • | Revenue Stream: Royalties build long-term value in oncology supportive care.
|
|
| |
This deal positions Curatis for multi-region breakthroughs in brain edema management.
|
| |
C2N Expands Alzheimer’s Blood Test Access in South Korea with BeauBrain Partnership
|
| |
|
| |
C2N Diagnostics has teamed up with BeauBrain Healthcare to launch PrecivityAD2 blood test in South Korea for Alzheimer’s assessment in patients 50+ with mild cognitive impairment or dementia symptoms.
|
| |
Why It Matters
|
| |
| • | Clinical Performance: 91% accuracy, 90% sensitivity, 92% specificity vs. Amyloid PET (npj Dementia); outperforms standard care (JAMA).
|
|
| • | Target Population: Enables early detection in aging Asia-Pacific markets.
|
|
| • | Regulatory Wins: U.S. FDA Breakthrough Device; UK MHRA registration.
|
|
| |
Strategic Focus
|
| |
| • | Asia Market Entry: BeauBrain drives local clinician access and adoption.
|
|
| • | Diagnostic Innovation: Shifts Alzheimer’s from invasive imaging to simple blood tests.
|
|
| • | Global Momentum: Paves way for broader international rollout.
|
|
| • | Patient Impact: Speeds diagnosis for timely intervention.
|
|
| |
This partnership brings game-changing Alzheimer’s diagnostics to Korea’s doorstep.
|
| |
PRISM and Receptor.AI Join Forces to Crack ‘Undruggable’ Targets with AI-Driven Discovery
|
| |
PRISM BioLab and Receptor.AI have partnered to create an AI-physics guided platform merging PRISM’s PepMetics (3D peptide-mimicking small molecules) with Receptor.AI’s AI design engine—targeting tough intracellular PPIs, membrane proteins, and receptor networks for oral small molecules.
|
| |
Why It Matters
|
| |
| • | Tech Synergy: Combines PepMetics α-helix/β-turn mimics with AI molecular design.
|
|
| • | Undruggable Focus: Unlocks PPIs, membrane proteins, complex receptors.
|
|
| • | Initial Target: Receptor linked to metabolic diseases like obesity.
|
|
| |
Strategic Focus
|
| |
| • | Discovery Acceleration: Speeds hit/lead/clinical candidate identification.
|
|
| • | Platform Power: AI-navigated, physics-based for novel oral therapies.
|
|
| • | Pharma Partnerships: Open to collaborators for broader applications.
|
|
| • | Disease Impact: Pioneers next-gen metabolic and beyond treatments.
|
|
| |
This alliance redefines small molecule discovery for tomorrow’s toughest targets.
|
| |
|
| |
| | Strategic Buys, Bold Bets: This Week’s Pharma & Medtech Deals
|
|
|
|
|
| |
Enodia Acquires Kezar’s Sec61 Program to Advance Next-Gen Targeted Protein Modulation
|
| |
|
| |
Enodia Therapeutics has acquired Kezar Life Sciences’ Sec61-based discovery/development assets to enhance Sec61 selectivity and fast-track clinical progress. Kezar gets $1M upfront + up to ~$127M milestones and tiered royalties.
|
| |
Why It Matters
|
| |
| • | Deal Value: $1M upfront + $127M milestones/royalties for Sec61 assets.
|
|
| • | Platform Edge: Selective Sec61 translocon modulation blocks disease proteins, spares healthy ones.
|
|
| • | Asset Boost: Integrates Kezar insights for better translational knowledge.
|
|
| |
Strategic Focus
|
| |
| • | Selectivity Deep Dive: Refines mechanisms for precise protein targeting.
|
|
| • | Clinical Acceleration: Speeds path to key milestones.
|
|
| • | Therapy Expansion: Builds next-gen protein modulation pipeline.
|
|
| • | IP Strength: Secures foundational Sec61 tech for long-term leadership.
|
|
| |
This acquisition powers Enodia’s charge into precision protein degradation.
|
| |
Servier Makes $2.5B Bet on Pediatric Oncology with Day One Biopharma Acquisition
|
| |
Servier has agreed to acquire Day One Biopharmaceuticals for ~$2.5B at $21.5/share in cash, via tender offer and second-step merger; closes Q2 2026.
|
| |
Why It Matters
|
| |
| • | Deal Scale: $2.5B full equity buyout accelerates precision oncology push.
|
|
| • | Pediatric Focus: Bolsters leadership in low-grade glioma and rare cancers.
|
|
| • | Pipeline Depth: Adds early-stage to Phase III assets for adult/pediatric needs.
|
|
| |
Strategic Focus
|
| |
| • | Oncology Expansion: Integrates Day One’s targeted therapies.
|
|
| • | Global Ambition: Aligns with Servier’s 2030 innovation goals.
|
|
| • | Unmet Needs: Targets high-need cancers worldwide.
|
|
| • | Portfolio Synergy: Strengthens from research to commercialization.
|
|
| |
This acquisition cements Servier’s pediatric oncology dominance.
|
| |
Agilent Expands Diagnostics Ambitions with $950M Biocare Medical Acquisition
|
| |
Agilent Technologies has agreed to acquire Biocare Medical for $950M all-cash from Excellere Partners/GHO Capital; integrates into Life Sciences and Diagnostics Group, closes Q4 2026.
|
| |
Why It Matters
|
| |
| • | Deal Value: $950M all-cash bolsters pathology/IVD portfolio.
|
|
| • | Market Reach: Expands into clinical/research pathology labs.
|
|
| • | Timing: Pending approvals, closes by year-end 2026.
|
|
| |
Strategic Focus
|
| |
| • | Antibody Enhancement: Strengthens diagnostics menu for precision medicine.
|
|
| • | Innovation Acceleration: Speeds pathology tool development.
|
|
| • | Group Synergy: Fits Agilent’s Life Sciences and Diagnostics vision.
|
|
| • | Customer Impact: Meets demands in advanced diagnostics.
|
|
| |
This move positions Agilent as a diagnostics powerhouse.
|
| |
Medtronic Strengthens Stroke Care Portfolio with $550M Scientia Vascular Acquisition
|
| |
|
| |
Medtronic has agreed to acquire Scientia Vascular for $550M, plus undisclosed earn-outs/milestones, to bolster its neurovascular stroke intervention tools.
|
| |
Why It Matters
|
| |
| • | Deal Value: $550M base + potential earn-outs for advanced access platform.
|
|
| • | Portfolio Fit: Integrates with Medtronic’s existing stroke tech ecosystem.
|
|
| • | Clinical Scope: Covers hemorrhagic/ischemic stroke workflows.
|
|
| |
Strategic Focus
|
| |
| • | Access Innovation: Adds Scientia’s platform for complex cases.
|
|
| • | Full Workflow: Enables diagnose-access-treat continuum.
|
|
| • | Physician Enablement: Enhances tools for neurovascular procedures.
|
|
| • | Market Leadership: Deepens stroke intervention dominance.
|
|
| |
This acquisition supercharges Medtronic’s end-to-end stroke care.
|
| |
|
| |
| | Next-Gen Assets, Big Data: This Week’s Breakthrough Headlines
|
|
|
|
|
| |
Phase II/III SUCCESSOR-2 Trial
|
| |
|
| |
Relapsed/Refractory Multiple Myeloma (RRMM)
|
| |
BMS announced topline data from the Phase II/III SUCCESSOR-2 trial of mezigdomide (oral) + carfilzomib + dexamethasone vs. carfilzomib + dexamethasone alone in patients with relapsed/refractory multiple myeloma.
|
| |
Key Details
|
| |
| • | Primary endpoint (PFS): Met in Phase III with improved PFS for mezigdomide triplet (specific HR not disclosed).
|
|
| • | Safety profile: Consistent with known characteristics of the combination and mezigdomide.
|
|
| • | Ongoing evaluation of overall survival (OS) and long-term safety.
|
|
| |
Next Steps
|
| |
| • | Full data presentation at upcoming scientific conference.
|
|
| • | Submission to global health authorities to support regulatory discussions.
|
|
| |
Asset Snapshot
|
| |
CELMoD + proteasome inhibitor + steroid triplet elevates RRMM standards post-relapse.
|
| |
Atopic Dermatitis (AD)
|
| |
Pfizer reported positive topline data from a multi-stage Phase II trial of tilrekimig (and ompekimig) in moderate-to-severe atopic dermatitis (AD), highlighting next-gen potential in immunology.
|
| |
Key Details
|
| |
| • | Primary endpoint (EASI-75 at Week 16): Met; placebo-adjusted rates: 38.7% (low dose), 51.9% (mid), 49.4% (high).
|
|
| • | Stage 2 maintenance: Competitive efficacy with quarterly dosing; higher doses showed clinically meaningful improvements.
|
|
| • | Ongoing: Stage 3 (biologic-experienced adults); Stage 4 (ompekimig dose-ranging).
|
|
| |
Next Steps
|
| |
| • | Phase III planning underway; pivotal AD trial to start later 2026.
|
|
| • | Additional trials: Phase II asthma; Phase IIb/III COPD.
|
|
| |
Asset Snapshot
|
| |
Next-gen immunology asset (tilrekimig) targets AD, asthma, and COPD with strong dose-response profile.
|
| |
Psoriatic Arthritis (PsA)
|
| |
|
| |
UCB announced positive topline results from the Phase III BE BOLD trial, where Bimzelx (bimekizumab) showed superior disease activity reduction vs. risankizumab in adults with active psoriatic arthritis (PsA; N=553; biologic-naïve or TNF-i inadequate responders).
|
| |
Key Details
|
| |
| • | Primary endpoint (ACR50 at Week 16): Met; Bimzelx superior for joint symptom/disease activity improvement.
|
|
| • | Patient population: Biologic-naïve or post-TNF inhibitor (inadequate response/intolerance).
|
|
| • | MoA: Humanized IgG1 mAb selectively inhibiting IL-17A and IL-17F.
|
|
| |
Next Steps
|
| |
| • | Full data presentation at upcoming scientific congress.
|
|
| |
Asset Snapshot
|
| |
Dual IL-17A/F inhibitor Bimzelx raises PsA treatment bar vs. IL-23 competitor.
|
| |
Chronic Limb-Threatening Ischemia (CLTI)
|
| |
Aplagon dosed the first patient with APAC (IV) in the Phase IIa HEALING trial (Finland) for Peripheral Arterial Occlusive Disease (PAOD) progressing to CLTI, advancing a novel therapy for limb-threatening ischemia.
|
| |
Key Details
|
| |
| • | Trial design: ~42 CLTI patients across 4 cohorts; assesses safety, efficacy, thrombo-inflammatory biomarkers.
|
|
| • | Parallel study: PET imaging with 89Zr-labeled APAC in PAOD (results H1 2026).
|
|
| • | Prior data: Successful Phase I in AV fistula maturation (encouraging outcomes, no safety issues).
|
|
| |
Next Steps
|
| |
| • | HEALING topline data expected 2026.
|
|
| • | Phase II AV fistula maturation failure trial planned in EU (2026).
|
|
| |
Asset Snapshot
|
| |
Thrombo-inflammatory modulator APAC targets CLTI, PAOD, and dialysis access complications.
|
| |
Phenylketonuria (PKU)
|
| |
Otsuka shared early (embargoed) data from an open-label extension (OLE) study of repinatrabit (JNT-517; oral) in adolescents with PKU, signaling strong potential across responder types.
|
| |
Key Details
|
| |
| • | Cohort 1 (75 mg BID): 67% mean Phe reduction from baseline by Day 56 (OLE Month 1); 100% response rate (incl. sapropterin responders/non-responders, treatment-naïve).
|
|
| • | Cohort 2: Evaluating 150 mg dose.
|
|
| • | Phase III PheORD: 120 adults randomized to repinatrabit/placebo (6 weeks), then crossover (primary completion late 2026; full 2028).
|
|
| |
Next Steps
|
| |
| • | Randomized period data and further OLE findings forthcoming.
|
|
|
| |
Asset Snapshot
|
| |
Oral Phe-lowering agent repinatrabit targets broad PKU population with rapid, consistent reductions.
|
| |
Ornithine Transcarbamylase (OTC) Deficiency
|
| |
Ultragenyx reported topline results from the Phase III Enh3ance study of DTX301 (AAV8 gene therapy) in OTC deficiency, showing meaningful ammonia control and clinical improvements vs. placebo.
|
| |
Key Details
|
| |
| • | Ammonia reduction: 18% drop in 24-hour levels at Week 36; normalized in 8/9 with abnormal baseline.
|
|
| • | Metabolic shifts: 27% ↓ ammonia scavengers; ~13% ↑ protein intake (levels stayed normal).
|
|
| • | Patient-reported (Week 24): 71% "much improved" (PGIC) vs. 0% placebo; 64% moderate/substantial symptom gains vs. 19%.
|
|
| |
Next Steps
|
| |
| • | Primary endpoint evaluation ongoing.
|
|
| • | Additional data expected H1 2027.
|
|
| |
Asset Snapshot
|
| |
One-time AAV8 gene therapy DTX301 offers sustained ammonia control and PRO benefits in OTC deficiency.
|
| |
Type 2 Diabetes (T2D)
|
| |
|
| |
Insulet presented positive data from the EVOLUTION 2C feasibility study of its fully closed-loop (FCL) automated insulin delivery system in Type 2 diabetes at ATTD 2026.
|
| |
Key Details
|
| |
| • | Primary improvement: Time-in-Range (TIR) reached 68% (24% ↑ vs. standard injection therapy); no insulin boluses required.
|
|
| • | Safety: TBR <70 mg/dL median 0.14%; no severe hypoglycemia or DKA events (N=24; ages 16-70).
|
|
| • | Patient retention: >90% continued to extension phase.
|
|
| |
Next Steps
|
| |
| • | EVOLVE pivotal trial launch 2026.
|
|
| • | 510(k) FDA submission 2027; potential commercial launch 2028.
|
|
| |
Asset Snapshot
|
| |
Fully closed-loop AID system expands automated glucose control to Type 2 diabetes population.
|
| |
|
| |
| | Regulatory Pulse: Approvals, Priority Reviews & Fast-Track Milestones
|
|
|
|
|
| |
Major Regulatory Moves
|
| |
|
| |
The regulatory landscape saw a wave of major approvals, priority reviews, and milestone filings, signaling continued momentum across immunology, oncology, and rare diseases.
|
| |
• Bristol Myers Squibb secured U.S. FDA approval for Sotyktu (deucravacitinib) to treat adults with active Psoriatic Arthritis, expanding the reach of its TYK2 inhibitor beyond dermatology.
|
| |
• Incyte received European Commission approval for Zynyz to treat Squamous Cell Carcinoma of the Anal Canal, offering a new immunotherapy option in a rare but aggressive cancer setting.
|
| |
• AstraZeneca and Daiichi Sankyo advanced their antibody-drug conjugate with the U.S. FDA granting Priority Review for Enhertu in HER2-positive early breast cancer, accelerating the regulatory timeline for the blockbuster therapy.
|
| |
• Johnson & Johnson gained European Commission approval for Akeega to treat Metastatic Hormone-Sensitive Prostate Cancer, strengthening its oncology portfolio in prostate cancer care.
|
| |
• LENZ Therapeutics announced the EMA’s acceptance of its Marketing Authorization Application for Vizz, a potential treatment for Presbyopia, marking a key regulatory step in the ophthalmology space.
|
| |
• Johnson & Johnson also submitted an EMA application for Tecvayli targeting relapsed/refractory Multiple Myeloma, aiming to expand access to its bispecific antibody therapy in Europe.
|
| |
• ARTHEx Biotech received U.S. FDA Fast Track designation for ATX-01 for the treatment of Myotonic Dystrophy Type 1, potentially accelerating development for this rare neuromuscular disorder.
|
| |
• GSK earned U.S. FDA approval for Arexvy, expanding its use to prevent Respiratory Syncytial Virus (RSV) disease, reinforcing the company’s position in the rapidly evolving RSV vaccine market.
|
| |
|
| |
| | MedTech Pulse: Breakthrough Devices, FDA Clearances & Surgical Innovation
|
|
|
|
|
| |
Surgical & Diagnostic Innovation: FDA Approvals in Focus
|
| |
|
| |
The MedTech landscape continues to advance with clinical milestones, regulatory clearances, and next-generation surgical technologies aimed at improving diagnostic precision and treatment outcomes.
|
| |
• QIAGEN secured U.S. FDA clearance for its QIAstat-Dx GI Panels on the QIAstat-Dx Rise Syndromic Testing System, enhancing rapid multiplex gastrointestinal pathogen detection for clinical diagnostics.
|
| |
• Cairn Surgical announced a U.S. FDA De Novo 510(k) submission for its Breast Cancer Locator (BCL) System, a surgical guidance technology designed to improve lumpectomy accuracy and tumor localization in Breast Cancer procedures.
|
| |
|
| |
| | Natera Unveils Zenith Genomics for Rare Disease Breakthroughs
|
|
|
|
|
| |
Zenith Genomics: Natera’s Rare Disease Game-Changer
|
| |
|
| |
Natera has officially launched Zenith Genomics, a next-generation whole genome sequencing (WGS) assay designed to enhance detection of rare and ultra-rare diseases across the U.S.
|
| |
Zenith Genomics combines whole genome sequencing with long-read confirmation, enabling the detection of complex genomic features such as tandem repeat expansions. This advanced approach supports more accurate diagnoses and empowers improved clinical management for patients with challenging genetic conditions.
|
| |
The technology was developed by MyOme and, through an exclusive partnership with Natera, will now be available to U.S. healthcare providers. Early data from the platform were highlighted at the ACMG Annual Clinical Genetics Meeting 2026, showcasing its potential to reshape rare disease diagnostics.
|
| |
|
| |
|
| |
Healthcare & Biotech Brief: From Multi-Billion Deals to Trial Shocks
|
| |
Momentum never stops. Key deals and breakthroughs include Lonza’s $3B CDMO-focused divestment, Servier’s $2.5B pediatric oncology acquisition, Enodia’s Sec61 program buy, and Agilent’s $950M Biocare deal. Immutep shocks the biotech world, halting its Phase III immunotherapy trial and dropping 80% premarket. Other highlights: GSK, George Medicines, Curatis, C2N, PRISM/Receptor.AI, Ultragenyx, Insulet, Natera, plus top regulatory approvals and MedTech innovations, shaping the week’s market-moving insights.
|
| |
Stay Ahead with PharmaShots Weekly
|
| |
Biopharma never slows down — breakthrough data surfaces overnight, billion-dollar deals reshape markets, and regulatory decisions shift competitive landscapes in real time. In an industry moving at this velocity, your intelligence can’t afford to fall behind.
|
| |
PharmaShots Weekly cuts through the noise to deliver what truly matters: pivotal pipeline updates, regulatory inflection points, clinical breakthroughs, strategic partnerships, and competitive dynamics — distilled into a concise, executive-ready briefing you can absorb in minutes, not hours.
|
| |
Every Monday at 8:00 AM EST, receive a decision-focused snapshot of the forces shaping the global pharma and biotech ecosystem — curated for leaders who act on insight, not information overload.
|
| |
If this edition sparked new ideas, turn that momentum into a habit. Subscribe to PharmaShots Weekly for intelligence that is concise, credible, and crafted for decision-makers across R&D, Competitive Intelligence, Strategy, and Business Development.
|
| |
Know someone who values signal over noise? Forward this edition.
Spotted an insight worth amplifying? Share it on LinkedIn and tag us — we love spotlighting sharp perspectives.
|
| |
The industry moves fast.
Your intelligence should move faster.
|
| |
| | Tell your success story to world!
Reach out to us [email protected] for CXO Talks or Viewpoint interview, because your story matters!
|
|
|
|
|
| |
|
0 comments